Gene Silencing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Gene Silencing Market Trends and Insights

Expansion of Approved RNAi and Antisense Therapeutics

The growing number of approved RNAi and antisense therapies supports demand in the gene silencing market. The FDA approved AMVUTTRA (vutrisiran) for cardiomyopathy of ATTR amyloidosis in March 2025. In the HELIOS-B trial, AMVUTTRA reduced all-cause mortality by 36% through 42 months and lowered cardiovascular events in the approved population. Qfitlia (fitusiran) became the sixth Alnylam-discovered siRNA approved by the FDA in March 2025 for hemophilia A or B and reduced annualized bleeding rates by 90% in clinical trials. The European Medicines Agency authorized Tryngolza (olezarsen) for familial chylomicronemia syndrome in September 2025, while the European Commission authorized REDEMPLO (plozasiran) in June 2026. Approvals across multiple indications enable developers to expand established product value without repeating the full cost of early-stage discovery.

Advances in GalNAc and Lipid Nanoparticle Delivery

GalNAc conjugation remains central to the gene silencing market because it enables targeted delivery to hepatocytes. A 2025 study found that ribofuranose-based GalNAc-siRNA conjugates provided stronger liver targeting and a longer elimination half-life than the established L96 GalNAc construct used for inclisiran.^{[1]Zhang Y, “Ribofuranose-Based GalNAc-Conjugated siRNA Enhances the Liver-Targeted Delivery,” Molecular Therapy: Nucleic Acids, cell.com.} In 2026, a computational platform used pharmacokinetic and pharmacodynamic data from all seven FDA-approved GalNAc-siRNA drugs to predict the performance of new candidates, including SAL0132. Research also showed that GalNAc-modified five-component lipid nanoparticles supported hepatocyte-specific targeting through ASGPR-mediated endocytosis. In February 2026, Ribo Life Science licensed its GalSTAR bispecific siRNA platform to Madrigal Pharmaceuticals for USD 60 million upfront and potential milestones of up to USD 4.4 billion, highlighting demand for platforms that target two genes.

Expansion into Cardiometabolic and Chronic Diseases

Cardiometabolic diseases are expanding the potential treatment population for the gene silencing market beyond rare conditions. CRISPR Therapeutics will present Phase 1a data for CTX310 at the European Society of Cardiology Congress in August 2026. At the highest dose, a single infusion produced a mean ANGPTL3 reduction of 73%, a triglyceride reduction of 55%, and an LDL reduction of 49%. Early data from VERVE-102 and clinical research on PCSK9-related approaches also indicate continued development of therapies for durable LDL reduction. Inclisiran exceeded USD 1 billion in annual sales in 2025, demonstrating commercial demand for a chronic cardiovascular siRNA therapy with twice-yearly dosing. As PCSK9, ANGPTL3, and angiotensinogen approaches progress, dosing frequency and patient access are likely to influence product selection alongside clinical outcomes.

AI-Enabled Design of Silencing Sequences and Delivery Systems

Artificial intelligence is becoming increasingly important in gene silencing discovery and delivery activities. In June 2026, FENNEC, a fine-tuned ensemble neural network model, reported improved predictions of chemically modified siRNA efficacy across gene-level and scaffold-level validation tests. The model was also tested on a new AHSA1-targeting dataset, supporting its application across previously unseen chemistries. In May 2026, SpeciMiR, a target-specific microRNA design framework trained on 2.2 million miRNA-mRNA pairs, reported stronger on-target binding for liver disease targets than FDA-approved siRNA benchmarks. In the second quarter of 2026, Alnylam Pharmaceuticals formed a strategic collaboration with Inceptive Nucleics to combine its RNAi data with foundation models for discovery. Companies with extensive biological data may be better positioned to apply these tools, while smaller developers may rely more heavily on external technology partnerships.

Extrahepatic Delivery and Blood-Brain Barrier Limitations

While liver delivery is well established, effective delivery to the brain, muscle, and lungs remains a key limitation in the gene silencing market. A 2025 study found that an intravenous albumin-binding lipid-siRNA conjugate reached nearly all brain endothelial cells and sustained gene silencing.^{[2]Qin Z-X, “GalNAc-Modified Five-Component Lipid Nanoparticles for Liver-Targeted Delivery,” Journal of Materials Chemistry B, doi.org.} However, it did not detect delivery into brain parenchymal tissue, limiting its applicability for several central nervous system targets. Sarepta Therapeutics and Dyne Therapeutics advanced muscle-targeted platforms that required tissue-specific delivery strategies. Until non-liver delivery improved in cost, safety, and performance, many programs remained focused on liver-expressed targets.

High Treatment Cost and Payer Reimbursement Pressure

Treatment costs and reimbursement requirements slowed the broader adoption of gene silencing therapies. Many approved RNA therapies initially targeted rare diseases, while their use expanded to chronic conditions with significantly larger patient populations. Inclisiran exceeded USD 1 billion in annual sales in 2025, although healthcare systems faced early access and readiness challenges as it entered broader cardiovascular care. Established generic cardiovascular medicines also created pricing pressure for newer RNA therapies. The Centers for Medicare & Medicaid Services launched its Cell and Gene Therapy Access Model in January 2025, using outcomes-based contracts for selected gene therapies under Medicaid.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product and Service: Approved Therapeutics Support Product Leadership

Products held 79.89% of the gene silencing market in 2025, supported by revenue from approved RNAi and antisense medicines. RNAi therapies remain the largest product category, with GalNAc-siRNA treatments addressing metabolic, cardiovascular, and hematologic conditions. The seven FDA-approved GalNAc-siRNA drugs generated direct sales, royalty, and milestone revenue for developers and licensors. CRISPR-Cas9 products remain in the early stages of commercial development, while the first-in-human CTX310 trial at Cleveland Clinic is expected to report one-year follow-up data in August 2026.

Antisense oligonucleotides remain an established component of the gene silencing industry. Tryngolza received European authorization in September 2025 for familial chylomicronemia syndrome, while Ionis Pharmaceuticals has zilganersen under FDA review for Alexander disease, with a PDUFA action date in September 2026. Services are projected to grow at a 14.35% CAGR through 2031, driven by demand for external synthesis, formulation, bioanalytical testing, and regulatory support. Alnylam is investing USD 250 million in its Norton, Massachusetts, facility to add an enzymatic ligation platform, with operations expected by late 2027.

By Application: Drug Discovery Leads While Therapeutics Manufacturing Grows Fastest

Drug Discovery & Development accounted for 55.45% of the gene silencing market in 2025. Researchers use RNAi and CRISPR tools to validate targets and identify leads across oncology, neurology, metabolic diseases, and infectious disease programs. These tools support targets that conventional small molecules cannot readily address. Arrowhead Pharmaceuticals licensed its clinical-stage ARO-PNPLA3 MASH program to Madrigal Pharmaceuticals in May 2026 under terms that could exceed USD 1.6 billion.

Therapeutics Manufacturing is projected to grow at a 15.46% CAGR from 2026 to 2031, driven by the transition of approved RNAi and antisense therapies to larger production volumes. The gene silencing industry also supports agricultural applications through spray-induced gene silencing. Research published in 2025 reported that sprayable RNAi plant-protection products received approval in the United States and China, while the European Union continues to evaluate regulatory frameworks. Differing EPA and EFSA requirements may delay multinational deployment, while FDA and EMA guidance provides a clearer pathway for therapeutic manufacturing.

By End User: Pharmaceutical and Biotechnology Companies Lead Demand

Pharmaceutical & Biotechnology Companies held 42.67% of the gene silencing market in 2025. These companies use RNAi and antisense platforms across internal research pipelines and in-licensing transactions. AbbVie entered a collaboration with ADARx Pharmaceuticals in May 2025, paying USD 335 million upfront for siRNA programs in neuroscience, immunology, and oncology. Genentech partnered with SanegeneBio in February 2026, providing USD 200 million upfront and up to USD 1.5 billion in milestone payments.

Academic & Research Institutes are projected to grow at a 13.67% CAGR through 2031. These institutions use silencing tools in functional genomics, agricultural science, clinical diagnostics, and therapeutic research. CROs and CMOs support the gene silencing market through outsourced synthesis, bioanalytical testing, and regulatory services. The Others category includes agricultural biotechnology companies and government-supported research programs, while machine learning platforms increasingly support siRNA design.

Geography Analysis

North America held 41.75% of the gene silencing market in 2025. The region benefits from approved RNAi and antisense products, extensive pharmaceutical research infrastructure, and established reimbursement systems. Alnylam reported 99% insurance coverage for AMVUTTRA in hereditary ATTR polyneuropathy, with most patients paying no out-of-pocket costs. Health Canada approved REDEMPLO in early 2026, expanding the therapy’s regional reach.

Europe also supports agricultural gene silencing research, although EFSA requirements differ from the EPA approach in the United States. Italy, Spain, and the Nordic countries contribute through contract research and academic licensing activities. AviadoBio expanded its vMiX RNAi platform license with King’s College London to all human therapeutic areas in June 2026. South America and the Middle East and Africa remain research-led markets, with commercial adoption expected to follow North America and Europe.

Asia-Pacific is projected to grow at a 13.56% CAGR through 2031. China’s clinical pipeline and cross-border licensing activities support the region’s role in the gene silencing market. Japan has demand for treatments targeting neurodegenerative and cardiometabolic diseases, and its regulators reviewed AMVUTTRA based on HELIOS-B data in early 2026. OliX Pharmaceuticals expanded its siRNA licensing activity with China’s Hansoh Pharmaceutical through a two-sequence agreement in August 2026.